Revance Therapeutics (RVNC) has released an update to notify the public and investors about its officers.
Revance Therapeutics, Inc.’s Compensation Committee has set the 2024 Bonus Program and equity award mix for its executive officers. CEO Mark Foley’s bonus will solely depend on company-wide goals, while other executives will have individual performance modifiers. Bonuses can exceed targets if performance surpasses goals. Foley’s target bonus is 75% of his base salary, with his equity entirely in performance stock units, while other executives have a mix of performance stock units and restricted stock units, with bonuses ranging from 50% to 55% of their base salaries.
For further insights into RVNC corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
